Recode Health Ventures

Recode Health Ventures is a San Francisco-based venture capital firm founded in 2022, focused on transforming the healthcare sector through innovative technologies. The firm's founders are dedicated to revolutionizing healthcare by leveraging exponential technologies to improve patient outcomes and streamline healthcare delivery. By identifying and supporting emerging companies within the healthcare space, Recode Health Ventures aims to foster advancements that address critical challenges in the industry.

Vishal Gulati

Co-Founder and Managing Partner

Armen A. Vidian

Managing Partner

3 past transactions

LabGenius

Series B in 2024
LabGenius Ltd is a biopharmaceutical company based in London that focuses on discovering new biological molecules through the integration of artificial intelligence, automation, and synthetic DNA. Founded in 2012, the company has developed a robotic platform known as EVA, which acts as a robot scientist capable of designing, conducting, and learning from its own experiments. LabGenius specializes in developing next-generation protein therapeutics aimed at addressing unmet medical needs, including conditions like Inflammatory Bowel Disease. Their innovative approach utilizes advanced machine learning and synthetic biology to engineer the properties of protein drugs, enhancing attributes such as protease stability and tissue penetration. This technology enables the efficient creation of protein therapeutics, providing physicians with access to cutting-edge treatments developed through robotic automation.

Verisian

Pre Seed Round in 2023
Verisian is a technology company that specializes in accelerating drug development and approval processes. It offers a data platform designed for health professionals, which enhances trial integrity and traceability, enabling real-time analysis and monitoring of studies. This platform ultimately helps to bring safe and effective therapies to patients faster by streamlining the drug testing and FDA approval process.

Sensible Biotechnologies

Pre Seed Round in 2023
Operator of a cell-based biotechnology platform designed to produce messenger ribonucleic acid(mRNA) therapeutics and vaccines. The company's platform uses cell engineering, computational biology, and precision fermentation to optimize the production of vaccinia capping enzymes, enabling medical professionals to provide optimal medicines to their patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.